TheraRadar
Data updated: May 26, 2026

AMICAR (aminocaproic acid)

Oncology Approved 1964-06-03

AMICAR is indicated for the treatment of Fibrinolysis; Aplastic Anemia; Abruptio Placentae; Hepatic Cirrhosis; Prostate Cancer; Lung Cancer; Stomach Cancer; Cervical Cancer; Hematuria.

Source: FDA Label • EPIC PHARMA LLC
4
Indications
--
Phase 3 Trials
3
Priority Reviews
61
Years on Market

Details

Status
Discontinued
First Approved
1964-06-03
Routes
INJECTION, ORAL
Dosage Forms
INJECTABLE, TABLET, SOLUTION

Companies

Active Ingredient: AMINOCAPROIC ACID

AMICAR Approval History

1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
84 FDA actions from 1964 to 2009 · 1 indication expansions
Feb 2009 SUPPL
Label · Labeling
Aug 2008 SUPPL
Label · Labeling
Aug 2004 SUPPL
Label · Labeling

What AMICAR Treats

9 indications

AMICAR is approved for 9 conditions since its original approval in 1964. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Fibrinolysis
  • Aplastic Anemia
  • Abruptio Placentae
  • Hepatic Cirrhosis
  • Prostate Cancer
  • Lung Cancer
  • Stomach Cancer
  • Cervical Cancer
Source: FDA Label

AMICAR Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to AMICAR

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMINOCAPROIC ACID
AMINOCAPROIC ACID
9 shared
AJENAT PHARMS
Shared indications:
FibrinolysisAplastic AnemiaAbruptio Placentae +6 more
AMINOCAPROIC ACID IN PLASTIC CONTAINER
AMINOCAPROIC ACID
9 shared
Pfizer
Shared indications:
FibrinolysisAplastic AnemiaAbruptio Placentae +6 more
AKEEGA
ABIRATERONE ACETATE
1 shared
Johnson & Johnson
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT04814433 results posted 20-01420 Ph 4 terminated Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
NCT02030821 results posted Pro00050108 Ph 4 completed TXA vs. Amicar in Total Knee and Hip Arthroplasty
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AMICAR FDA Label Details

Indications & Usage

FDA Label (PDF)

AMICAR is indicated for the treatment of Fibrinolysis; Aplastic Anemia; Abruptio Placentae; Hepatic Cirrhosis; Prostate Cancer; Lung Cancer; Stomach Cancer; Cervical Cancer; Hematuria.

Track AMICAR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.